Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it has entered into a partnership with Laboratorios Legrand S.A("Legrand”), the pharmaceutical company in Colombia, to market its Denosumab biosimilars. Under the agreement, Legrand is responsible for the registration and commercialization of the products in Colombia and Ecuador.

Mr. Huiguo Hu, Board Member and Senior Vice President of Mabwell, said, “We are pleased to build the strategic collaboration with Legrand for Colombia and Ecuador market, work together to register and commercialize denosumab biosimilars in Colombia and Ecuador. As one of the strategic countries in Latin America, Colombia is the priority for pharmaceutical companies to enter the Latin America market. This partnership represents our first step in Latin America market, and we trust that it will further improve the accessibility of denosumab to local patients in these countries.”

About Legrand

With more than 35 years, Legrand is a 100% Colombian company. Legrand has abundant portfolio, more than 550 employees, commits to the health and well-being of Colombians. Legrand is also the high respected pharmaceutical company in Colombia.